Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

CrossBoss First Shows Promise for Antegrade CTO PCI

News Conference News TCT 2017

CrossBoss First Shows Promise for Antegrade CTO PCI

TCT Daily Staff

November 07, 2017

News Opinion Off Script TCT 2017

Off Script: Focusing on the Future

October 31, 2017

DARE Supports Drug-Coated Balloon as Alternative to DES for Any In-Stent Restenosis

News Conference News TCT 2017

DARE Supports Drug-Coated Balloon as Alternative to DES for Any In-Stent Restenosis

October 30, 2017

News Industry News

Eurocor announces the presentation of the 12 months data of the Freeway Stent Study at CIRSE in Copenhagen

September 19, 2017

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

News Conference News VIVA 2017

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

September 13, 2017

News Industry News

Medtronic IN.PACT Admiral DCB Global Two Year Data and IN.PACT SFA Four Year Data Presented in VIVA Late Breaking Clinical Trials

September 12, 2017

Registry Confirms Long-term Durability of Drug-Coated Balloon for Femoropopliteal Lesions

News Daily News

Registry Confirms Long-term Durability of Drug-Coated Balloon for Femoropopliteal Lesions

August 03, 2017

‘Surprising’ Uptick in Rates of Revascularization for In-Stent Restenosis

News Daily News

‘Surprising’ Uptick in Rates of Revascularization for In-Stent Restenosis

July 18, 2017

Slimmest Stent to Date Looks Promising in Small Study

News Conference News EuroPCR 2017

Slimmest Stent to Date Looks Promising in Small Study

May 19, 2017

News Industry News

Eurocor announces the completion of the Freeway Stent Study

April 04, 2017

TWENTE: Resolute and Xience Stents Show Comparable Outcomes Up to 5 Years

News Daily News

TWENTE: Resolute and Xience Stents Show Comparable Outcomes up to 5 Years

Michael O'Riordan

January 20, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.